Diego Handeri Hermes, Thaís Martins Costa, B. D. Brito, C. M. Dutra, I. Silva, Júlia Ramos Cerchi, Lucas Rodrigues de Santana, Mateus Corrêa Silva, Thaís Caroline Gonçalves Ribeiro, Vínicius Gomes de Morais
{"title":"A DESCONTINUAÇÃO DA PRESCRIÇÃO DA ASPIRINA PARA PREVENÇÃO PRIMÁRIA DE DOENÇAS CARDIOVASCULARES: UMA REVISÃO NARRATIVA","authors":"Diego Handeri Hermes, Thaís Martins Costa, B. D. Brito, C. M. Dutra, I. Silva, Júlia Ramos Cerchi, Lucas Rodrigues de Santana, Mateus Corrêa Silva, Thaís Caroline Gonçalves Ribeiro, Vínicius Gomes de Morais","doi":"10.34119/bjhrv3n4-360","DOIUrl":null,"url":null,"abstract":"INTRODUCTION: Diseases of the circulatory system are the main cause of death in Brazil and worldwide. The use of aspirin in secondary prevention is consolidated, due to its antiplatelet effect, however, its real benefits have been discussed in the primary prevention of cardiovascular diseases (CVDs). Thus, our objective was to evaluate the benefit-damage relationship of primary prophylaxis of cardiovascular events. RESULTS: Articles from systematic reviews, randomized controlled trials and meta-analyzes were selected in the last five years and revealed that the results of the aspirin group had a lower rate of myocardial infarction, transient ischemia, ischemic stroke and an increased risk of gastrointestinal bleeding and intracranial in all studied populations, in addition to the significant increase in the risk of death in the elderly population. DISCUSSION: These studies had shown, in general, little or no benefict in aspirin’s use as a primary prevention of CVDs, and an increased risk of bleeding in the studied groups. CONCLUSION: Therefore, the prescription of aspirin for primary prevention of CVDs should be individualized, comparing the benefits with the bleeding risk. Key-words: Aspirin, primary prevention, cardiovascular diseases. Brazilian Journal of health Review Braz. J. Hea. Rev., Curitiba, v. 3, n. 4, p. 11072-11087 jul./aug. 2020. ISSN 2595-6825 11075","PeriodicalId":369447,"journal":{"name":"Tecnologias aplicadas nas ciências da saúde (Vol.1)","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tecnologias aplicadas nas ciências da saúde (Vol.1)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34119/bjhrv3n4-360","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION: Diseases of the circulatory system are the main cause of death in Brazil and worldwide. The use of aspirin in secondary prevention is consolidated, due to its antiplatelet effect, however, its real benefits have been discussed in the primary prevention of cardiovascular diseases (CVDs). Thus, our objective was to evaluate the benefit-damage relationship of primary prophylaxis of cardiovascular events. RESULTS: Articles from systematic reviews, randomized controlled trials and meta-analyzes were selected in the last five years and revealed that the results of the aspirin group had a lower rate of myocardial infarction, transient ischemia, ischemic stroke and an increased risk of gastrointestinal bleeding and intracranial in all studied populations, in addition to the significant increase in the risk of death in the elderly population. DISCUSSION: These studies had shown, in general, little or no benefict in aspirin’s use as a primary prevention of CVDs, and an increased risk of bleeding in the studied groups. CONCLUSION: Therefore, the prescription of aspirin for primary prevention of CVDs should be individualized, comparing the benefits with the bleeding risk. Key-words: Aspirin, primary prevention, cardiovascular diseases. Brazilian Journal of health Review Braz. J. Hea. Rev., Curitiba, v. 3, n. 4, p. 11072-11087 jul./aug. 2020. ISSN 2595-6825 11075
在巴西和世界范围内,循环系统疾病是导致死亡的主要原因。由于其抗血小板作用,阿司匹林在二级预防中的应用得到了巩固,然而,其真正的益处在心血管疾病(cvd)的一级预防中尚未得到讨论。因此,我们的目的是评估初级预防心血管事件的利弊关系。结果:从近5年的系统综述、随机对照试验和荟萃分析中选择的文章显示,阿司匹林组在所有研究人群中心肌梗死、短暂性缺血、缺血性卒中发生率较低,胃肠道出血和颅内风险增加,此外老年人群死亡风险显著增加。讨论:这些研究表明,一般来说,阿司匹林作为心血管疾病的一级预防很少或没有益处,并且在研究组中出血风险增加。结论:因此,阿司匹林用于心血管疾病一级预防的处方应个体化,并将获益与出血风险进行比较。关键词:阿司匹林;一级预防;心血管疾病巴西健康评论杂志布拉兹。j .头脑。Rev., Curitiba, v. 3, n. 4, p. 11072-110872020. Issn 2595-6825 11075